HLA class II restricted T cell reactivity to a developmentally regulated antigen  shared by leukemic cells and CD34+ early progenitor cells. by Goulmy, E.A.J.M. et al.
HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated
Antigen Shared by Leukemic Cells and CD34+ Early Progenitor Cells
By Tuna Mutis, Ellen Schrama, Simone Α Ρ van Luxemburg-Heijs, J Η F Falkenburg, Cornelis J Μ Melief,
and Eis Goulmy
After allogeneic bone marrow transplantation (BMT), the
beneficial graft-versus-leukemia (GVL) effect but also the
life-threatening graft-versus-host disease (GVHD) are medi-
ated by Τ cells of the grafted marrow The Identification of
leukemia cell-reactive Τ cells and their ligands are, there-
fore, crucial for the development of new anti leukemia strat-
egies. Here we describe a leukemia-reactive allo-HLA class
II restricted CD4+ T-cell clone, 6.2, isolated from a healthy
individual after Stimulation with allogeneic leukemic cells.
Clone 6 2 recognizes leukemic cells from several AML pa-
tients without showing reactivity to unfractioned peripheral
blood mononuclear cells, monocytes, Β cells, T-cell blasts,
and proximal tubulus epithelial cells. Interestingly, clone 6.2
ALLOGENEIC bone marrow transplantation (BMT) isthe therapy of choice for the treatment of several he-
matologic malignancies, such as leukemia ' Today the occui-
rence of graft-versus-host disease (GVHD) remains a major
comphcation of the BMT 2 5 In the current view, both GVHD
and graft versus leukemia (GVL) effects of the BMT are
mediated by donor denved mature Τ cells Deplction of Τ
cells from the BM effectively prevents GVHD, but lesults
in a high rate of leukemia relapses 6 8 Furtheimoie, patients
with relapsed chronic myeloid leukemia can be effectively
treated by admimstration of donor lymphocytes 9 Several
clmical tnals show a direct association between GVL and
GVHD and suggest that the GVL effect may be the reflection
of the antihost reactivity against leukemic cells and is, there
fore, not separable from G V H D 4 1 0 " On the othei hand,
recent analyses of a large number of patients in the Interna-
tional Bone Marrow Tiansplantation Register point out that
GVL can be observed independent of senous GVHD 12 Also,
results from expenmental munne modeis suggest that GVL
and GVHD can be mediated by separate as well as by ldenti-
cal T-cell populations n 16 These data have been also sup-
ported by some recent studies in humans where T-cell lmes
and clones could be isolated, and these preferentially recog-
mzed leukemic cells 17 2 2 These in vitro studies, together with
the clmical data, suggest that leukemia-associated antigens
must exist Ne\ ertheless, in most cases the isolated Τ cells
appeared not solely leukemia specific or difficult to mamtam
in vitro I8 21
In our search for Τ cells that are reactive with leukemia-
associated antigens, we have investigated the in vitro T-cell
response of a healthy mdividual against the leukemic cells
of an HLA class II mismatched unrelated AML patient with
AML Ml classification We have isolated several T-cell
clones, of which the majonty was directed against subtle
HLA class II diffeiences between the responder and the
stimulator One CD4+ prohferative and cytotoxic T-cell
clone recognized only leukemic cells from several AML
patients in an allo-HLA-DR restricted fashion This T-cell
clone also recognized HLA class II matched BM cells Nei-
ther CD34~, more differentiated precursors m the BM nor
mononuclear cells in the peripheral blood (PB) are recog-
nized by Τ cell clone 6 2, suggesting that lts target antigen is
also recognizes BM cells derived from healthy individuals
and inhibits the colony formation of myeloid and erythroid
cell lineages. In the BM, clone 6.2 recognizes only CD34+
early precursor cells but not CD34 , more differentiated cells.
Thus, the target antigen of clone 6.2 is developmentally reg-
ulated and expressed only by leukemic cells and CD34+ early
progenitor cells in the hematopoietic System. We suggest
that targeting the T-cell immune response to leukemia-asso-
ciated, developmentally regulated antigens of the hemato-
poietic System can provide a basis for the Separation of GVL
from GVHD, and may lead to new therapeutic approaches
for residual and relapsed leukemia.
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expressed only on leukemic cells and on early hematopoietic
progenitor cells
MATERIALS AND METHODS
Isolation of PB Mononuclear Cells (PBMCs), Leukemic
Cells, and BM Cells
PBMCs or BM cells from healthy donors and acute myeloid leuke-
mia (AML) patients were isolated by Ficoll-hypaque (Pharmacia,
Uppsala, Sweden) density centrifugation Cell samples from AML
patients that contained greater than 95% morphologically recogmz-
able leukemic cells were further assigned as ' 'leukemic cells '' Leu-
kemic cells, PBMCs, and BM cells were cryopreserved in 10%
dimethyl sulfoxide and stored in liquid nitrogen until use
Isolation of Monocytes, Untransformed Β Cells, and BM
Cell Fractions
Patients' PBMCs or BM cells from healthy individuals were la-
beled with the indicated fiuorescein-conjugated antibodies (Becton
Dickinson) Monoclonal antibody (MoAb)-labeled cells were posi-
tively sorted using a fluorescein-activated cell sorter (FACS)
Epstein-Barr Virus-Transformed Β Lymphoblastoid Cell
Lines (EBV-BLCL)
PBMCs weie ineubated with EBV dunng 1 5 hours at 37°C After
washing, the cells were eultured in RPMI + 20% fetal calf serum
(FCS) in the presence of 30 Gy irradiated feeder cells consisüng of
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PBMCs from six random donors The EBV-transformed Β cells were
further expanded in RPMI + 10% FCS
Phytohemagglutinin (PHA) Blasts
PBMCs were cultured in the presence of 0 1 ^g/niL PHA for 3
days Activated T-cell blasts (PHA blasts) were further expanded
for three days using recombinant interleukin-2 (rIL-2) (20 U/mL)
containing culture medium
Generation of Leukemia-Reactive T-Cell Lines and Clones
Stimulator cells Leukemic cells of an AML paüent with
AML-Ml subclassification were used as stimulator cells The HLA
typmg of the leukemic cells was HLA-A3,-B7,-B62,-Cw7,-
DR13(DRBl*1302),-DR15(DRBl*1501), -DR52(Dw26)(-DRB3*0301),
-DQw6(DQB 1*0602, *0604), -DPB1*0301,*0601
Responder cells PBMCs of a healthy individual were used as
responder cells The HLA typing of the responder cells was HLA-
A3,-B7,-B62,-Cw7,-DR13(DRBl*130I),-DR15(DRB 1*1501), -
DR52(Dw25)(-DRB3*0202), -DQw6(DQBl*0602,*0603/07), -
DPB1*0401,*0402
Before the mduction of pnmary T-cell cultures, stimulator Jeuke-
mic cells were cultured for 72 hours with a cocktaü of cytokines
consisting of 800 U/mL granulocyte-macrophage colony-stimulating
factor (GM-CSF, tandly provided by Dr Osanto, Leiden, The Nether-
lands), 1,000 U/mL IL-4 (Genzyme, Leuven, Belgium), and 150 U/
raL tumor necrosis factor-a (TNF-α, Genzyme), in RPMI supple-
mented with 10% FCS, and antibiotics (penicilhn 100 U/mL, strepto-
mycin 100 /ig/mL) Α total of 107 cytokine-treated, irradiated (30
Gy) leukemic cells were cocultured with 107 responder cells in 5
mL of culture medium (RPMI supplemented with 15% human serum
[HS] and antibioücs), at 37°C, and 5% CO2 On day 6 20 U/mL of
rIL-2 was added in the culture On day 8 the T-cell line was restimu-
lated with irradiated leukemic cells On day 15 the T-cell line was
cloned by hmiüng diluüon at 0 3 cells/well in 96-well round-bottom
microtiter plates in the presence of a feeder cell mixture containing
irradiated PBMCs (30 Gy) from six random donors (1 Χ 106 cells/
mL), irradiated leukemic cells (30 Gy) (2 5 Χ 105 c/mL), 20 U/mL
rIL-2, and 1% Leucoagglutimn-A (Sigma, St Louis, MO) rIL-2, 20
U/mL, was added to the cultures every 72 hours The T-cell clones
were expanded by weekly restimulations with the above-descnbed
feeder cell-cytokine mixture and tested for leukemia-specific cyto-
toxic and prohferative activities
T-cell prohferatwn assays One to 2 Χ 104 responder Τ cells
were cocultured with irradiated stimulator cells (2 to 10 Χ 104 c/
well) in 96-well flat-bottom microtiter plates dunng 88 hours Six-
teen hours before harvesting the cultures were labeled with 0 5 μ θ
of 3H-thymidine The 3H-thymidine incorporation was determined
by liquid scintillation counting The results are expressed as the
mean of duphcate or tnplicate cultures The SEM of the results
never exceeded 15%
Cytotoxwity assays 51Cr-labeled target cells (3,000/well) were
incubated with senal dilutions of effector Τ cells in 96-well round-
bottomed microtiter plates (Costar 3799, Cambridge, MA) After 4
hours of incubation at 37°C, cell-free supernatants were obtained for
gamma counting The percent specific Iysis was calculated as fol-
Iows % Specinc Lysis = (Expenmental Release - Spontaneous
Release)/(Maximal Release - Spontaneous Release) X 100% Spon-
taneous release and the maximal release are the chromium release
of target cells in culture medium alone and in cullure medium con-
taining 1% Tnton-X 100 (Fluka, Buchs, Switzerland), respectivcly
To use as target cells, proximal tubulus epithelium cells (PTEC)
were trypsinated and seeded at 3,000 c/well in 96-well flat-bottom
microtiter plates After allowing adherence, TNF-a (150 U/mL) and
interferon-γ (IFN -γ) (200 U/mL) were added to the wells to induce
the HLA class II expression PTEC were cultured in the presence
of cytokines for 72 hours Twelve hours before the assay 51Cr (3
μθ/well) was added to the wells After washing, 5 lCr labeled, adher-
ent PTEC were used as target cells in cytotoxicity assays
Hematopowtic precursor cell (HPC) growth Inhibition assays
HPC growth Inhibition assays were performed as described pre-
viously23 Bnefly, 125 Χ 105 bone marrow mononuclear cells
(BMMNC) was mixed with effector Τ cells at different Τ ΒΜ cell
ratios in 0 2 mL of HPC culture medium (Iscove's modified Dulbec-
co's medium [IMDM] supplemented with 30% plasma, 0 5 % bovine
serum albumin [BSA], 0 47 g/L transfernn, 5 X 10 5mol/L mercaplo-
ethanol, and 10% culture supernatant of Τ ceils) The cells were then
either immediately resuspended to a final volume of 1 4 mL with
semisohd HPC medium supplemented with 10 ng/mL rGM-CSF, 50
ng/mL rIL-3 (both from Sandoz, Basel, Switzerland), 2 IU r-erythro-
poieün (Cilag AG Int, Zug, Switzerland), and 1 3% methyl cellulose,
or bnefly centnfuged (1,000g, 15 seconds) to establish BM-T-cell
contact and incubated for 4 hours at 37°C in 5% CO2 before transfer-
ring to the semisohd medium One milhliter of the semisohd suspen-
sion was plated in 30-mm plastic dishes and incubated at 37°C in 5%
CO2 After 14 days the number of erythrocyte burst-forming umts
(BFU-E), colony-forming umt-granulocyles (CFU-G), and CFU-
monocytes (CFU-M), defined as typical cell aggregates of more than
20 cells, were scored under an inverted microscope The percentage
HPC growth Inhibition is calculated as follows % HPC Growth Inhi-
bition = (1 - No of Colomes in the Presence of Effector Cells/No
of Colomes Without Effector Cells) X 100%
RESULTS
In Vitro Generation of Leukemw Reachve T-Cell Lines
and Clones
The PBMCs of a healthy individual were used to generate
in vitro T-cell responses agatnst leukemic cells of an unre-
lated AML patient The responder mdividual and the patient
were serologically HLA identical, but showed subtle differ-
ences in HLA-DR, -DP, and -DQ genotypings (see Materials
and Methods). Before using as stimulator cells, the leukemic
cells were cultured with GM-CSF, IL-4, and TNF-α dunng
72 hours to increase their antigen-presenting capacity. The
generated T-cell line showed prohferative and cytotoxic ac-
tivity against leukemic cells at day 8 (data not shown) Sev-
eral T-cell clones denved from this T-cell line were tested
against leukemic cells, patient's EBV-BLCL, and HLA-
typed PBMCs from healthy individuals. Based on the reac-
tion patterns, four types of T-cell clones could be di&tin-
guished (Fig 1) (1) The type I T-cell clones (n = 25) were
reactive agatnst both leukemic cells and EBV-BLCL Thus,
these clones were not able to discnminate leukemic from
nonleukemic cells (2) The type II T-cell clones (n = 7)
were reactive only to EBV-BLCL, suggesting that EBV-
associated antigens were recogmzed. (3) The type III T-cell
clones (n = 19) were reactive against leukemic cells but did
not show reactivity against patient's EBV-BLCL, suggesting
that their target antigen(s) were present on leukemic cells
but not on nonleukemic EBV-BLCL However, when these
T-cell clones were tested against a panel of PBMCs, which
expressed the mismatched HLA class II antigens of the pa-
tient, all T-cell clones recogmzed one of more PBMCs Thus,
type III T-cell clones were not directed against leukemia-
associated antigens, but most piobably to alloantigens that
were expressed by PBMCs but not by EBV-BLCL
Specific Recognition of Patient's Leukemic Cells by the
CD4+ T-Cell Clone 6 2
One remaming CD4+ T-cell clone, designated as 6 2, rec-
ogmzed leukemic cells but did not show reactivity against
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Fig 1. Specific recognition of original stimulator leukemic cells
by the CD4' T-cell clone 6.2. (A) The proliferative activity of different
types of T-cell clones against patient's leukemic cells {AML cells),
patient's EBV-BLCL, and HLA matched PBMCs. For each type of clone,
the reactivity of one representative clone is shown. The number of
clones displaying similar reactivity patterns is indicated in the brack-
ets. (B) The proliferative activity of T-cell clone 6 2 against leukemic
cells, patient's monocytes, patient's transformed or untransformed
Β cells, and unrelated PBMC that share HLA class II antigens with
the AML patient. CD14+ monocytes and CD19/20+ Β cells were iso-
lated from PBMC of the patient by FACS sorting. Similar results were
obtained in at least three independent experiments.
7 3.19 1 that is directed to HLA-DRB3 locus (HLA-DR52)24
Antibodies directed to HLA class I, HLA-DP, or HLA-
D Q 2 5 2 6 were not inhibitory The MoAb 7.3 19 1 did not m-
hibit the recognition of the leukemic cells by a control HLA-
DP-reactive T-cell clone (Fig 2A, nght panel) lllustrating
lts specific inhibitory effect on clone 6 2 Because all cells
that are positive for HLA-DRB 1*1302 express the DR52
subtype HLA-Dw26 (DRB3*0301), the antigen recognition
by clone 6 2 is restncted by HLA-Dw26. Note that the re-
sponder cells are also HLA-DR52-positive but are geno-
typically typed as HLA-DRB3*0202 (see Materials and
Methods) Thus, the T-cell clone 6.2 recognizes lts leukemia-
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EBV-BLCL, CD19/20+ untransformed Β cells, or CD14+
monocytes that were denved from the PBMCs of the patient
(Fig 1B) Furthermore, clone 6 2 did not show reactivity
against a psnel of PBMCs that shared HLA-class II antigens
with leukf rnic cells (Fig 1B) These results indicated that T-
cell clore 6 2 was not directed against antigens expressed
by PBMCs, monocytes, or Β cells but reacted to an antigen
that u, expressed only by leukemic cells.
T-Cell Clone 6 2 Is Restncted Via the Mio HLA-DRw26
Molecule
As shown in Fig 2A, the proliferative activity of the clone
6 2 agdinst leukemic cells was completely blocked by MoAb
Fig 2. T-cell clone 6.2 is restricted by HLA-DRB3 locus produet
HLA-Dw26 and speeifieally recognizes HLA-Dw26-positive leukemic
cells (A) Effect of HLA specific MoAbs on the recognition of leukemic
cells by T-cell clone 6 2 (left panel) and a control DP reactive T-cell
clone (right panel). The target speeificities of the MoAbs are indicated
in brackets. MoAbs were added in the proliferation assays at 1100
dilution. ND, not tested. (B) Proliferative activity of T-cell clone 6.2
(left panel) and the HLA-Dw26 specific alloreactive T-cell clone (right
panel) against different leukemic and nonleukemic cells Patients no.
2 and 3 are HLA-Dw26-positive AML-M1 patients; patients no.4 to
10 are HLA-Dw26-negative AML or ALL patients (3 AML-M1,1 AML-
M3,1 AML-M5,1 ALL patient). MoAb 17.3 19.1 is added in the assay.
CD14+ monocytes from patient no 2 were obtained from PBMC by
FACS sorting. EBV-BLCL and PHA blasts were also tested after cultur-
ing with GM-CSF (800 U/mL) + TNF-a (50 U/mL) + IL-4 (500 U/mL)
for 72 hours. The thymidine uptake of T-cell clone 6 2 alone and the
stimulator cells alone did not exceed 500 cpm.
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Fig 3. Specific cytotoxic activity of T-cell clone 6 2 against leukemic cells Patients no. 1 and 2 are leukemia patients with AML-M1
designation. EBV-BLCL and PHA blasts were also tested after culturing with GM-CSF (800 U/mL) + TNF-a (50 U/mL) + IL-4 (500 U/mL) for 72
hours. Adherent PTEC were prepared as targets as indicated in Materials and Methode. Percent specific release of target cells was determined
in 4-hour Standard Cr release assays.
associated target antigen in the context of a mismatched,
allo HLA-Dw26 (DRB3*0301) molecule
T-Cell Clone 6 2 Proliferates Against Other HLA-Dw26-
Positive AML Cells Without Showmg Reactivity to
Nonleukemic Cells
The T-cell clone 6 2 was subsequently tested against a
panel of leukemic and nonleukemic cells denved from differ-
ent leukemia patients (Fig 2B, left panel) Α CD4+ alloreac-
tive T-cell clone specific for the HLA-Dw26 molecule was
used as control (Fig 2B, nght panel) Beside lts reactivity
dgdinst the original stimuldtor leukemic cells of the AML-
Ml patient (no. 1) (Figs 1B and 2A), clone 6 2 recognized
two other leukemic cells from AML patients (nos 2 and 3)
(Fig 2B, left panel) These leukemic cells were also recog-
nized by the control HLA-Dw26 reactive T-cell clone (Fig
2B, nght panel), confirming the expression of HLA-Dw26
on the cell surface Note that the prohferative activity of
both clone 6 2 and HLA-Dw26 specific dlloreactive T-cell
clone against the leukemic cells of patient no 2 were blocked
by antibody 7 3 19 1, lllustrating the HLA-Dw26 depen-
dency of the recogmtion Leukemic cells from six HLA-
Dw26-negdtive AML or acute lymphobldstoid leukemia
(ALL) patients were not recognized either by clone 6 2 or
by the control HLA-Dw26-specific T-cell clone (Fig 2B)
The leukemic cell-specific reactivity of clone 6 2 IS fur-
ther demonstrated by absence of proliferation against differ-
ent nonleukemic cell types obtained from patients no 2 and
3 Figure 2B shows that clone 6 2 did not recognize the
EBV-BLCL and monocytes denved from patient no 2, clone
6 2 also failed to recognize PHA blasts or PBMCs denved
from the HLA-identical BM donors of patients no 2 and 3
The EBV-BLCL and PHA blasts that were treated with GM-
CSF/TNF-a/IL-4 Cocktail were also not stimulatory, mdicat-
mg that the target antigen of clone 6 2 was not induced on
BLCL or Τ cells by these cytokines All tested HLA-Dw26-
positive nonleukemic cells, including those that were treated
with cytokines, were recognized by the control Dw26-reac-
tive T-cell clone (Fig 2B, nght panel), showmg that all as-
sayed nonleukemic cells expressed the restncüon molecule
and were capable of stimulatmg Τ cells (Fig 2B, nght panel)
T-Cell Clone 6 2 Is Cytotoxic to Leukemic Bul Not to
Nonleukemic Cells
T-cell clone 6 2 not only possessed prohferative activity
against leukemic cells but also efficiently lysed the leukemic
cells (Fig 3) Similar to lts prohferative activity, the cytotoxic
activity of clone 6.2 was confined to leukemic cells Nonleu-
kemic cells such as PHA blasts or EBV-BLCL denved from
the patients no 1 and 2 or from their HLA-identical BM
donors were not lysed (Fig 3). BLCL or PHA blasts that
were treated with the GM-CSF/TNF/IL-4 Cocktail were also
not lysed (Fig 3)
To assess whether nonhematopoietic cells can express the
target antigen of clone 6 2, an HLA-DRB3*0301 -positive
PTEC hne was tested as target cell (Fig 3) Clone 6.2 and
a control dlloreactive T-cell hne that is directed to HLA-
DRB1*13O2 and HLA-DRB3*0301 allo-determinants were
used as effector cells Because PTECs do not constitutively
express HLA class II, they were eultured with 200 U/mL
IFN-γ + 150 U/mL TNF-α during 72 hours to induce HLA
class II expression The control dlloreactive T-cell hne
showed a nonsignificant lysis against untreated PTEC which
lacked HLA-cldss II The mduction of HLA class II expres-
sion by IFN-γ and TNF-α led to the recogmtion of the PTEC
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Fig 4. Specific recognition of HLA-Dw26-positive BM early pro-
genitor cells by T-cell clone 6.2. (A) HLA-Dw26-positive or -negative
BM cells from healthy individuals were used to stimulate clone 6.2
(left panel) and the control HLA-Dw26-specific alloreactive T-cell
clone (rlght panel) in 88-hour Standard proliferation experiments. (B)
MoAb 7.3.19.1 is added in the assay. (C) Different subsets of BM
cells were obtained by FACS sorting after labeling with appropriate
antibodies, irradiated, and usad in proliferation experiments as stim-
ulator cells at 5 X 10* cells/well.
by the control alloreactive T-cell line only, suggesting that
the PTEC did not expressed the target antigen of clone 6.2.
T-Cell Clone 6 2 Recognizes CD34+ Hematopoielic
Progenitor Cells and Inhibits the Growth of Erythroid,
Monocytic, and Granulocytic Cell Lineages
T-cell clone 6.2 was tested against a panel of BM cells
derived from healthy individuals (Fig 4A, left panel). Like-
wise, the control HLA-Dw26-specific alloreactive T-cell
clone, clone 6.2, recognized all HLA-Dw26-positive BM
cells but did not recognize HLA-Dw26-negative BM cells
(Fig 4A). The proliferation of clone 6.2 against BM cells
was inhibited by the antibody 7.3.19.1, confirming its HLA-
DR-restricted reactivity (Fig 4B). As expected, the PBMC
derived from the HLA-Dw26-positive BM donors were not
recognized (Fig 4B). These results suggested that the clone
6.2 might recognize a developmentally regulated antigen that
is expressed only by early progenitor cells present in the
BM. To address this assumption, several FACS sorted BM
cell populations were tested for their capacity to stimulate
T-cell clone 6.2 (Fig 4C). T-cell clone 6.2 recognized the
unsorted BM cells, CD34+ early progenitor cells, CD34+,
CD33+ early myeloid cell precursors, but not CD34" cells,
including CD34~~, CD14+ monocytic lineage and CD34",
CD15+ granulocytic cell lineage. These results indicated that
the target antigen recognized by the antileukemic T-cell
clone 6.2 was expressed by CD34+ BM early progenitor
cells but not by more differentiated cells, including PBMCs.
Note that the control HLA-Dw26-specific alloreactive T-
cell clone recognized all cell subsets, indicating that the
unresponsiveness of clone 6.2 to CD34" cells was not caused
by a lack of stimulatory capacity (Fig 4C, right panel).
Because T-cell clone 6.2 displays cytotoxic activity, we
addressed the question of whether it could also lyse BM
cells and inhibit the outgrowth of different hematopoietic
cell lineages. Therefore, we used BM cells as target cells in
cytotoxicity assays (Fig 5) and in parallel we performed
HPC growth Inhibition assays (Fig 6). Α CD8+ HLA-A2-
specific CTL clone was used as control.
T-cell clone 6.2 showed specific cytolysis against two
HLA-Dw26-positive, unfractionated BM cells. As ex-
pected, HLA-Dw26-negative BM cells were not lysed (Fig
5, left panel). The moderate levels of lysis observed against
these unfractionated BM cells was not surprising because
clone 6.2 was expected to recognize only CD34+ cells in
the BM. The control HLA-A2-specific CD8+ alloreactive
T-cell clone significantly lysed the BM cells that were HLA-
A2-positive (Fig 5, right panel).
In HPC growth Inhibition assays (Fig 6), clone 6.2
strongly inhibited the outgrowth of BFU-E, CFU-G, and
CFU-M from two HLA-Dw26-positive BM (BM no. 1 and
BM no. 2) at T:BM ratios as low as 0.3:1. HLA-Dw26-
negative BM (BM no. 10, BM no. 11) were not inhibited,
showing that the HPC Inhibition was specific and dependent
on antigen presentation by BM cells. Likewise, the control
HLA-A2-specific CTL inhibited the HPC growth from only
HLA-A2-positive BMs no. 1, 10, and 11. Both clone 6.2
and alloreactive T-cell clone inhibited the number of the
growing colonies, and no difference in the size of the colo-
nies was observed, suggesting that the further outgrowth of
the colonies was not inhibited. Furthermore, neither clone
6.2 nor the CD8+ alloreactive clone inhibited the HPC
growth when the Τ cells and the BM cells were only mixed
immediately before plating in the semisolid culture medium
(data not shown), indicating that the Inhibition of HPC
growth was dependent to cell-cell contact. These results were
similar to those obtained by other CD8+ CTL directed to
alloantigens or to minor histocompatibility antigens.21
Taken together, the strong HPC growth Inhibition by clone
6.2 may reflect its cytotoxic activity against CD34+ early
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Fig 5. Cytotoxic activity of
clone 6.2 to BM cells. Unfraction-
ated BM cells were tested as tar-
get cells for clone 6 2 (left) and
for an HLA-A2-specific, CD8+ al-
loreactive CTL (right) in 4-hour
Standard CML assays.
precursor cells However, other mechamsms such as mduc-
tion of apoptosis via fas-fasL mteractions cannot be ex-
cluded
DISCUSSION
After an allogeneic BMT mature Τ cells present in the
graft inoculum appear to play d major role in the ehmination
of residual leukemic cells 6 9 The understanding of the nature
of the T-cell response directed to leukemic cells and the
Identification of leukemia-associated T-cell antigens IS the
basis of new therapeutic methods against leukemia This
lssue was the mam focus of the present study
Over the past few years Η became clear that the proper
activation of naive T-cell precursors m pnmary in vitro cul-
tures requires efficient antigen presentation supported by
strong costimulatory Signals dehvered by the antigen pre-
senting cell (APC) 2 7 In this respect, leukemic cells may not
function as proper APC since they usually lack or weakly
express costimulatory molecules such as B7 1 and B7 2 This
may be the reason why in some studies antileukemic T-cell
lines and clones were reported to be functionally or physi-
cally unstable in culture Therefore, we decided to culture
leukemic cells with GM-CSF, IL-4, and TNF-α These cyto-
kines, which are known to generate adequate APC from
monocytes,2830 also increased the antigen-presenting capac-
lty of acute myeloid leukemia cells (manuscript in prepara-
tion)
Usmg this strategy, we investigated pnmary T-cell re-
sponses induced against allogeneic leukemic cells Beside
T-cell clones that were reactive to leukemic cells and pa-
tient's EBV-BLCL, we have isolated other alloreactive T-
cell clones that recognized leukemic cells, HLA-matched,
allogeneic PBMCs, but not patient's EBV-BLCL (Fig 1A,
type III clones) These latter T-cell clones are probably di-
rected to allo-HLA determinants, which are apparently ab-
sent on EBV-BLCL
More mterestmgly, we have isolated a T-cell clone, desig-
nated as " 6 2," recogmzing an antigen present on vanous
leukemic cells but absent on nonleukemic cells isolated from
the PB, and on the kidney-denved PTEC This CD4+ T-cell
clone appeared to recogmze lts target antigen not in a self-
restncted but in an allo HLA-DR-restncted fashion In this
respect our results are in agreement with previous studies of
Sosman et al,17 18 who also have shown that allogeneic Τ cells
can display specific antileukemic activity m vitro Similar to
the Τ cells descnbed by Sosman et al, the antileukemic T-
cell clone 6 2 descnbed here is CD4+, class II restncted,
and not only prohferates but also displays cytotoxic activity
against leukemic cells Thus, lt is plausible that GVL effect
after BMT can be mediated also by antileukemic CD4+ Τ
cells Some recent studies indeed suggest that CD4+ Τ cells
can mediate GVL effects without the apparent inducüon of
GVHD 31 Moreover, in a recent clmical tnal, the GVL effect
of the bufty coat transfusion was preserved by the depletion
Fig 6 HPC growth Inhibition
by T-cell clone 6 2. T-cell clone
6 2 is preincubated with BM cells
at indicated T-cell.BM cell ratios
for 4 hours at 37°C The cells
were then transferred into semi-
solid HPC growth medium and
cultured in cell culture dishes to
allow HPC growth. The colony
formation in semisolid medium
is determined by light-micros-
copy after 10 days. Percent Inhi-
bition of the HPC growth was de-
termined as follows % Inhibition
= (1 - No. of Colonies in the
Presence of T-Cell Clone/No of
Colonies in the Absence of T-Cell
Clone ) κ 100%.
110,
BM#1 (HLA-A2+, -Dw26*)
clone 6 2
antl-HLA A2 CTL
BFU-E CFU-G CFU-M
-o- -o
BM#2 (HLA-A2', -Dw26*)|BM#10 (HLA-A2*. -Dw26") BM#11 (HLA-A2*, -Dw26')
0 3 1 1 1 31 03 1 11 3.1 03 1
T: BM cell ratio
11 31 0 3 1 1 1 31
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of CD8+ cells, whereas the GVHD was largely prevented
after this procedure 3 2
So far httle is known about the nature of the leukerma-
associated antigens that tngger T-cell immune responses
Several investigators consider leukemia-specific fusion pro-
teins, such as the charactenstic BCR-ABL fusion protein in
chronic myeloid leukemia (CML), as potential candidates
for targeting the T-cell immune response specifically to leu-
kemic cells 3 3 Although Τ cell responses can be generated
against the BCR-ABL fusion peptides, lt has not been con
vincmgly shown that BCR-ABL fusion product is naturally
expressed in the context of HLA rnolecules In acute leuke-
mids a vanety of turnoi-specific chromosome abnormalities
occur Although the fusion products of these chromosomal
translocations can be also considered as target antigens for
the development of leukemia specific therapies, not a laige
percentage of patients can be cured by such strategies be-
cause of the interindividual Variation in the chromosomal
abnormalities However, several of these divers chromo-
somal translocations led to the activation of common tran-
scnption factors that are important in differentiation 3 4 As
yet lt is not known whether these developmcntally regulated
antigens could tngger T-cell immune responses and seive
as leukemia-associated T-cell antigens Our current results
suggest that possibly such developmentally regulated anti-
gens can be recognized by Τ cells The HLA-DR restncted
T-cell clone 6 2 descnbed here specifically recognizes leuke-
mic cells from several AML patients and reacts to CD34+
BM cells without showing reactivity against CD34 BM cells
or against nonleukemic cells denved from PBMC The target
antigen of clone 6 2 is also not present on a nonhematopoi-
etic system-denved cell line PTEC Although we weie not
able to test other somatic tissue cells, and thus lt still remams
possible that an othei cell type can be recognized, so far
clone 6 2 shows a very limited target cell specificity m the
hematopoietic System The most hkely explanation of this
specific target cell specificity is that clone 6 2 recognizes
a developmentally regulated antigen of the hematopoietic
System, which is involved in the differentiation of early pro
genitor cells This antigen is also expressed on leukemic
cells that are arrested in an early stage of the differentiation
Because the Τ cell clone effectively inhibits the outgrowth
of hematopoietic precursor cells and lyses the leukemic cells,
the use of this clone for the treatment of leukemia after BMT
may result in ehmination of lesidual leukemic cells in the
PB and their precursors in the BM without the nsk of GVHD
The mam cnticism against such a therapeutic approach is
that the T-cell clone 0 2 will also lecognize grafted BM
and presumably will not allow the outgrowth of several cell
lineages This nsk can be avoided by transplantation of an
HLA-Dw26-neg<itive, thus a one allele HLA DR mis-
matched Β Μ graft, because the T-cell clone 6 2 will recog-
nize lts target antigen only in the context of HLA-Dw26 lt
is obvious that in such a transplantation setting the BM graft
should be T-cell depleted to avoid the nsks of senous GVHD
and the rejection of the CTL clone Alternatively, furmshmg
the T-cell clone 6 2 with a suicide gene, such as Hsv-tk
gene, may allow the control of the T-cell clone in vivo belore
BMT
In conclusion, our results suggest that targeting the Τ cell
immune response to the developmentally regulated antigens
of the hematopoietic System may be possible, and lead to
new approaches in the leukemia treatment
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